# SUPERNUS PHARMACEUTICALS, INC. (SUPN) · Edgar & Edgarette company card

> Supernus Pharmaceuticals, Inc. (SUPN) grew revenue 8.6% in FY2025 to $719 million, operating margin -8.7% against a -3.8% median for pharmaceutical preparations, equity 73.1% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 1356576 · fiscal year ended 2025-12-31 · 5 audited years read · [page](https://www.pops4.com/boards/company/SUPN) · [JSON](https://www.pops4.com/boards/company/SUPN.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $719M |
| Revenue growth, 1 year | 8.6% |
| Revenue growth per year | 5.5% |
| Operating margin | -8.7% (prior year 12.3%) |
| Net margin | -5.4% |
| Operating cash flow | $47M |
| Capital spending | $1M |
| Free cash flow | $46M |
| Cash | $128M |
| Long-term debt | — |
| Total assets | $1.5B |
| Total equity | $1.1B |
| Equity ÷ assets | 73.1% |
| Return on equity | -3.6% |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: 5.11 (safe zone)
- Piotroski F: 5 of 9 (middling)
- Beneish M: -2.54 (below the −1.78 line)
- Health Harbor boat: Sound ship · one warning sign · operating loss: a margin of -8.7% in FY2025
- Cash Compass: In between · no clear cash pattern yet

## Edgarette's reading

Exposure: revenue $719.0M (FY2025). Experience: revenue up 8.6% on the year, up 5.5% a year over 4 years; operating margin -8.7%, down from 12.3%. Soundness: equity 73.1% of assets, return on equity -3.6%. Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $629.6M and $879.7M next year (method v4.1: its own 4-year record of growth weighed at 50% against $100M–1B filers; across 2019–2025, 69.0% landed inside, 83.4% on the one year the method never saw). In a shock year the stress range is $578.5M to $960.7M. A statistical range, not company guidance. Against peers (114 filers, $50M+ revenue, pharmaceutical preparations): operating margin -8.7% against a -3.8% median; growth 8.6% against 13.7%.

Range logged 2026-11-01, receipt 224e06d2467f0a9e, status open. A statistical range, not company guidance.

## Health Watch, last 12 months

- Item 3.01 Exchange listing notice or transfer: 1, latest 2026-11-02 ([filing](https://www.sec.gov/Archives/edgar/data/1356576/000110465926121103/0001104659-26-121103-index.htm))
- Item 5.02 Director or officer change: 2, latest 2026-08-03 ([filing](https://www.sec.gov/Archives/edgar/data/1356576/000110465926089425/0001104659-26-089425-index.htm))

## Recent filings

- 8-K · filed 2026-11-02 · 3.01 Notice of Delisting or Failure to Satisfy a Listing Rule · [filing](https://www.sec.gov/Archives/edgar/data/1356576/000110465926121103/0001104659-26-121103-index.htm)
- 8-K · filed 2026-11-02 · 1.01 Entry into a Material Definitive Agreement; 2.01 Completion of Acquisition or Disposition of Assets; 2.03 Creation of a Direct Financial Obligation; 3.03 Material Modifications to Rights of Security Holders; 5.01 Changes in Control of Registrant; 5.03 Amendments to Articles or Bylaws; Change in Fiscal Year; 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1356576/000110465926121014/0001104659-26-121014-index.htm)
- 10-Q · filed 2026-10-29 · [filing](https://www.sec.gov/Archives/edgar/data/1356576/000135657626000051/0001356576-26-000051-index.htm)
- 8-K · filed 2026-10-29 · 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1356576/000135657626000050/0001356576-26-000050-index.htm)
- 8-K · filed 2026-10-26 · 1.02 Termination of a Material Definitive Agreement; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1356576/000135657626000045/0001356576-26-000045-index.htm)
- 8-K · filed 2026-10-22 · 8.01 Other Events; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1356576/000110465926117937/0001104659-26-117937-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0001356576.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1356576

## Cite

POPS4, Edgar & Edgarette: SUPERNUS PHARMACEUTICALS, INC. (SUPN) company card, from the company's own SEC filings, accessed 2026-11-03, https://www.pops4.com/boards/company/SUPN. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.